KBY Biotech Indexv0.0.34
Search
← Pipeline|Zanulemzoparlimab

Zanulemzoparlimab

Phase 3
MOR-4063
By Morphic Ther (Lilly)
Source: Trial-derived·Trials: 1
Modality
Cell Therapy
MOA
CD3xCD20
Target
AHR
Pathway
Fibrosis
FTDPBCIPF
Development Pipeline
Preclinical
~Dec 2020
→ ~Mar 2022
Phase 1
~Jun 2022
→ ~Sep 2023
Phase 2
~Dec 2023
→ ~Mar 2025
Phase 3
Jun 2025
→ Apr 2028
Phase 3Current
NCT03162157
2,051 pts·FTD
2025-06→2028-04·Active
2,051 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-04-122.0y awayPh3 Readout· FTD
Trial Timeline
Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
P3
Active
Catalysts
Ph3 Readout
2028-04-12 · 2.0y away
FTD
Active|StartCompletionToday
Trials (1)
NCTPhaseIndicationStatusNEP
NCT03162157Phase 3FTDActive2051OS
Competitors (10)
DrugCompanyPhaseTargetMOA
PFE-2901PfizerPhase 2AHRSOS1i
LLY-1184Eli LillyNDA/BLAC5CD3xCD20
ZanuderotideNovartisPhase 1/2VEGFCD3xCD20
AZN-1715AstraZenecaPhase 3AHRFXIai
NVO-1361Novo NordiskPhase 3CD38CD3xCD20
ZorizanubrutinibNovo NordiskPhase 1BTKCD3xCD20
BAY-6520BayerPhase 2AHRTROP-2 ADC
PexamavacamtenDaiichi SankyoNDA/BLATIGITCD3xCD20
ITC-1028Intra-CellularPhase 2BCMACD3xCD20
SemasacituzumabJazz PharmaPhase 2AHRAuroraAi